Based on the important role of HDACs in both the gene expression and enzyme activity involved in the regulation of ER transcriptional activity, many studies have successfully used HDAC inhibitors to reverse the ER status in ER−negative breast cancer cells. Here, HDAC9 is linked to breast cancer.